logo

Altimmune Inc. (ALT)



Trade ALT now with
  Date
  Headline
12/20/2022 7:57:50 AM Altimmune Reports Positive Topline Results From 24-Week (12-Week Extension) Trial Of Pemvidutide In NAFLD
9/28/2022 7:39:20 AM Altimmune Doses First Dosing In Phase 2 MOMENTUM Trial Of Pemvidutide In Subjects With Obesity Or Overweight
4/1/2022 7:13:45 AM Altimmune Begins 48-week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
1/31/2022 7:15:48 AM Altimmune: FDA Clears IND Application For Phase 2 Clinical Trial Of Pemvidutide For Obesity
12/13/2021 6:09:19 AM Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/13/2021 6:08:48 AM Altimmune Appoints Richard Eisenstadt As CFO, Effective Dec 31
10/4/2021 7:23:51 AM Altimmune Begins 12-week Phase 1b Trial Of Pemvidutide In Subjects With Non-Alcoholic Fatty Liver Disease
9/28/2021 7:27:37 AM Altimmune Announces Positive Results From 12-week Phase 1 Trial Of Pemvidutide In Overweight And Obese Volunteers
6/16/2021 7:13:09 AM Altimmune Announces Positive Interim Data From ALT-801 Phase 1 Trial In Healthy Overweight And Obese Volunteers